in service - tirr gh
Post on 15-Apr-2017
19 Views
Preview:
TRANSCRIPT
Neuromuscular Diseases
Differential Diagnosis and Treatment Ideas
Ashley Spiegel, SPTTexas Woman’s University
ObjectivesClinicians will be able to...
● Understand pathology and symptoms of various neuromuscular diseases○ GBS○ AIDP○ CIDP○ TM○ ALS
● Prescribe treatments while regarding diagnosis-specific considerations ● Differentially diagnose based on two case studies
Guillain Barre SyndromeDefinition: rapidly evolving, immune-mediated peripheral neuropathy preceded by a triggering event (infection)1
Symptoms:
● Proximal weakness accompanied by tingling dysesthesias in U/LEs○ LEs more affected than UE
● Pain○ Shoulder girdle, back, posterior thighs○ Most severe at night
● Hypo/areflexic
Diagnosis:
● Electrodiagnostic examination ● Absent DTRs● Elevated protein in CSF● Progressive weakness
● Progression of symptoms over days - 4 wks● Cranial nerve involvement● Autonomic dysfunction
Guillain Barre Syndrome: Phases● Progressive: worsening symptoms; days - 4 wks
○ 73% reach lowest point of clinical function at 1 wk, 98% at 4 wks○ 30% require ventilatory assistance○ 20% mortality rate
● Plateau: persistent, unchanging symptoms; days
● Recovery: improvement in symptoms and functioning○ 85% achieve full and functional recovery within 6-12 months○ Maximal by 18 months past onset○ Relapse occurs in 3-5% of pts
Guillain Barre Syndrome: Subtypes1. Acute inflammatory demyelinating polyradiculopathy (AIDP)
2. Acute motor axonal neuropathy (AMAN)
3. Acute motor sensory axonal neuropathy (AMSAN)
4. Miller Fisher Syndrome
5. Acute panautonomic neuropathy
Chronic Inflammatory Demyelinating Polyradiculopathy Definition: GBS/AIDP, but longer...2
● Sensory loss and weakness progress beyond 4 wks● Not self-limiting or spontaneous - if untreated, 30% will progress to w/c
dependence
Guillain Barre Syndrome: TreatmentSpecific treatment:
● Intravenous immunoglobulin (IVIg) or plasmapheresis● Gabapentin for pain management
Supportive treatment:
● PT/OT/Speech3,4,5
○ Progressive phase: PROM and positioning, upright tolerance, functional training○ Plateau: energy conservation, A-AROM and AROM exercises○ Recovery phase: aerobic training, RROM
● Psychological stress
Transverse MyelitisDefinition: neurological disorder caused by inflammation across both sides of one level of the spinal cord; often caused by viral infections, abnormal immune reactions6,7
Symptoms:
● Weakness of U/LEs depending on the level of the lesion● Pain/sensory alteration● Spasticity● Hyperreflexia ● Bowel and bladder dysfunction
Diagnosis:
● MRI/CT● Blood test (to rule out HIV, SLE, B12 deficiency)● CSF (elevated protein and WBCs)
Transverse Myelitis: Treatments Specific treatment:
● Corticosteroids● Plasma exchange● Pain medications ● Baclofen● Gabapentin
Supportive treatment:
● PT/OT/Speech○ Strength, endurance, coordination, reduce spasticity, equipment training, pressure relief
● Psychological
Transverse Myelitis: Prognosis● Recovery begins 2 - 12 wks of onset, up to 2 years
○ No improvement within 3-6 months, complete recovery unlikely
● ⅓ good or full recovery ○ Normal gait pattern, minimal urinary or bowel effects and paresthesias
● ⅓ fair recovery ○ Spastic gait, sensory dysfunction, incontinence
● ⅓ no recovery at all ○ Bedridden
Amyotrophic Lateral SclerosisDefinition: progressive neurodegenerative disease affecting cells in the brain and spinal cord8,9
● Amyotrophy: “no muscle nourishment”● Lateral sclerosis: hardness, or scarring, in the lateral columns of the spinal cord
Symptoms: gradual onset, painless, progressive muscle weakness
● Classic, spinal ALS: muscle cramps/fasciculations (initially), asymmetric muscle weakness and atrophy
● Bulbar onset ALS: dysarthria, dysphagia, sialorrhea● Respiratory onset ALS: respiratory failure
Diagnosis:
● Electrodiagnostic tests● Blood and urine studies
● Spinal tap● MRI
● Muscle/nerve biopsy● Thorough neurological exam
Amyotrophic Lateral Sclerosis: Diagnostic Criteria4
Amyotrophic Lateral Sclerosis: TreatmentSpecific treatment4:
● Riluzole (Rilutek)● Drugs for spasticity, fatigue, muscle cramps
Supportive treatment3,4:
● PT/OT/Speech○ Low impact aerobic exercise, ROM, stretching○ Avoid vigorous exercise in later stages
Case StudiesDifferential Diagnosis
Patient #1● Female● Mid 50s● Symptoms:
○ LE weakness● Eval:
○ Tone: 0○ Clonus: 0 ○ Bed mobility: max A○ Transfers: max A○ Gait/stairs: does not occur
● D/C: after 10 day stent in rehab○ Bed mobility, transfers: mod I○ Gait: 1000’ RW; ramps, curbs, unlevel surfaces○ Stairs: 3 flights CGA
Patient #2● Male● Mid 60s● Symptoms:
○ LE weakness → UE weakness○ Bulbar symptoms ○ B ptosis○ Neurogenic bladder
● Eval:○ Strength: 2-○ Tone: 0○ Clonus: 0○ Bed mobility: total A○ Transfers: total A with mechanical lift○ Gait/stairs: does not occur
● D/C: not yet (6 wks since hospital admisison, 19 days in rehab)
Differential Diagnosis: ALS
Patient #1 Presentation Typical ALS Presentation Patient #2 Presentation
Sudden onset Gradual onset Sudden onset
✓ No pain Severe pain
✓ Progressive muscle weakness
✓
LMN only LMN + UMN signs LMN only
Differential Diagnosis: TM
Patient #1 Presentation Typical TM Presentation Patient #2 Presentation
✓ LE weakness U/LE weakness ✓
No pain Pain/abnormal sensation ✓
Flaccid Spasticity/hyperreflexia Flaccid
No bowel and bladder dysfunction
Bowel and bladder dysfunction
✓ Neurogenic bladder
Decreased signals MRI Decreased signals
Differential Diagnosis: GBS
Patient #1 Presentation Typical GBS Presentation Patient #2 Presentation
Stronger proximally Weaker proximally ✓
Inconsistent hypersensitivity/ no pain
Pain/hypersensitivity at shoulders, back, and thighs (severe night pain)
✓
Rapid improvements (1wk), no plateau
Progressive (4 wks), plateau, recovery (6-12 mos)
✓ 6 wks since dx; currently in plateau/recovery
GBS/AIDP CIDP TM ALS
Preceding infection Preceding infection Autoimmune, preceding infection
Unknown cause
Proximal > distal weakness Proximal > distal weakness Weakness in U/LEs below level of lesion
Asymmetric muscle weakness, fasciculations, atrophy
Pain/hypersensitivity, esp. at night (shoulders, back, thighs)
Pain/hypersensitivity, esp. at night (shoulders, back, thighs)
Sensory alteration below level of lesion
Hypotonicity and/or spasticity
Hypo and/or hyperreflexia
Bulbar signs (dysarthria, dysphagia, sialorrhea)
Bulbar signs (dysarthria, dysphagia, sialorrhea)
Bowel and bladder dysfunction
Bulbar signs (dysarthria, dysphagia, sialorrhea)
Progressive up to 4 wks followed by plateau; maximal at 18 months
Continues to progress beyond 4 wks, not self-limiting
Recovery within 2-12 wks; maximal at 2 years
No recovery, no cure
References1. Newswanger DL, Warren CR. Guillain-Barré Syndrome. American Family Physician. 2004;69(10):2405-2410.
http://www.aafp.org/afp/2004/0515/p2405.html. Accessed October 4, 2016.2. All About CIDP - GBS/CIDP Foundation International. GBSCIDP Foundation International.
http://www.gbs-cidp.org/cidp/all-about-cidp/. Accessed October 4, 2016.3. Danto A. PT Management of Other Neurological Conditions: MS, ALS, GBS, CNS Tumors. October 2016.4. Das R. Neuromuscular Diseases. June 2015.5. GBS/CIDP Foundation International. Guillain-Barre Syndrome, CIDP and Variants: Guidelines for Physical and
Occupational Therapy. https://www.gbs-cidp.org/wp-content/uploads/2012/01/PTOTGuidelines.pdf. Accessed October 4, 2016.
6. Transverse Myelitis Fact Sheet. U.S National Library of Medicine. http://www.ninds.nih.gov/disorders/transversemyelitis/detail_transversemyelitis.htm. Accessed October 4, 2016.
7. Disease Information - The Transverse Myelitis Association. The Transverse Myelitis Association. https://myelitis.org/living-with-myelitis/disease-information/. Accessed October 4, 2016.
8. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. U.S National Library of Medicine. http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_als.htm. Accessed October 4, 2016.
9. ALS Association. ALSA.org. http://www.alsa.org/. Accessed October 4, 2016.
Questions or comments?
top related